AskBio gets $235 million in gene therapy support

Posted by on Apr 12, 2019 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – Asklepios BioPharmaceutical, Inc (AskBio), a platform company playing a key role in North Carolina’s global gene therapy leadership, got a $235 million vote of confidence this week. The developer and manufacturer of Adeno-Associated Virus (AAV) gene therapies for underserved patient populations with rare and generally untreatable genetic disorders, announced a $225 million investment from TPG Capital and Vida Ventures in exchange for a minority stake in the company. As part of the transaction, AskBio’s founders and board members are co-investing $10...

Read More

Fresenius Kabi celebrates $100M pharma expansion, bringing 445 new jobs to Wilson

Posted by on Apr 8, 2019 in Newsroom | 0 comments

WILSON, N.C. – Fresenius Kabi, a global health care company based in Germany, hosted a topping off ceremony last week to celebrate the $100 million expansion of its pharmaceutical manufacturing campus in Wilson. The topping off ceremony was a traditional celebration of construction projects upon the installation of the topmost structural member – in this case, signing celebrants’ names on the final huge steel I-beam at the growing pharmaceutical production center in Wilson. The expansion will add at least 445 new jobs to the workforce of 100-plus at the Wilson County site by the...

Read More

HudsonAlpha Genomic Services Lab joins Discovery Life Sciences to form HudsonAlpha Discovery

Posted by on Apr 5, 2019 in Newsroom | 0 comments

HUNTSVILLE, AL. – The HudsonAlpha Institute for Biotechnology announced that the HudsonAlpha Genomic Services Lab (GSL) has signed an agreement with Discovery Life Sciences to form a new division of that company, HudsonAlpha Discovery. The move will build on the success of the Institute in developing a top-of-the-line sequencing lab by adding the global reach of Discovery Life Sciences and its sales force. This expands the reach of the Institute and brings more high-quality biotech jobs to the thriving campus. The HudsonAlpha Discovery division will be entirely on the HudsonAlpha...

Read More

Life science firm with Raleigh office developing blood tests for cancers raises $3.1M

Posted by on Apr 4, 2019 in Newsroom | 0 comments

RALEIGH, N.C. – Inanovate, an emerging life science company developing blood tests for cancer and other diseases which was once based in the Triangle, has raised $3.1 million in new funding. Inanovate, which has received backing from the North Carolina Biotechnology Center, maintains an operation in Raleigh. The company’s headquarters was moved to South Dakota in 2017. South Dakota Equity Partners, Sanford Frontiers and executive T. Denny Sanford led the investment. The company says it expects to add more funding to the round, a Series C, later this year. Funding will be used to...

Read More

Thermo Fisher pharma plant in Greenville to receive $74M upgrade

Posted by on Apr 4, 2019 in Newsroom | 0 comments

GREENVILLE, N.C. – A Thermo Fisher plant in Greenville that has become one of North Carolina’s largest pharmaceutical manufacturers, is getting another $74 million upgrade to support the growing global demand for biomanufacturing services and biologics products. The expansion of the Eastern North Carolina factory’s prefilled syringe (PFS) and vial-filling lines is part of a $150 million investment in three global fill & finish plants that also includes two in Italy. The company says the expansions will especially support demand for sterile liquid and lyophilized product...

Read More

Innovate Biopharma raises $9.7 million in new capital

Posted by on Apr 2, 2019 in Newsroom | 0 comments

RALEIGH, N.C. – Raleigh-based Innovate Biopharmaceuticals, a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, has raised around $9.7 million in new financing from 17 investors, according to a recent SEC filing. Under the deal, some 4.1 million shares of common stock will be sold at $4 per share, and up to 2.5 million shares at $2.56 per share. The deal is with SDS Capital Partners II LLC and other investors. The filing comes after the firm confirmed last month plans to raise millions ahead of the stage 3 clinical...

Read More